GLIMMER

Recruiting

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response

Lead sponsor

University of Alberta

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

Primary endpoint

•Lean mass

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07272837

Org study IDPro00153724

Timeline

Milestones

Study first posted2025-12-09actual

Study start2026-04-14estimated

Last update posted2026-04-20actual

Primary completion2027-12-31estimated

Study completion2028-04-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Individuals who are starting semaglutide and are able to attend study visits at the Mazankowski Alberta Heart Institute.

Inclusion criteria

•Adults 18-80 years of age

•Starting semaglutide for type 2 diabetes or weight loss

•Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion criteria

•Current use of semaglutide for more than 2 weeks

•Major recent heart issues or other severe health conditions

•Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)

•Dependence on a mobility aid (unable to participate in exercise MRI)

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Changes in skeletal and cardiac muscle mass

Time frame:12 months

Lean mass

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.